NCT05591027 is a Phase 1 clinical trial investigating the effects of Centella asiatica, a traditional medicinal herb, on cognitive function in patients with Alzheimer's disease. Centella asiatica, also known as gotu kola, has been used in traditional medicine systems for centuries to support cognitive function and nervous system health.
| Parameter |
Details |
| NCT Number |
NCT05591027 |
| Status |
Recruiting |
| Phase |
Phase 1 |
| Intervention |
Centella asiatica (herbal supplement) |
| Condition |
Alzheimer's Disease |
| Participants |
48 |
| Sponsor |
To be confirmed |
| Start Date |
2022 |
| Completion Date |
2024 |
Centella asiatica contains several bioactive compounds believed to support cognitive function:
- Triterpenoids: Asiaticoside, madecassoside, asiatic acid
- Flavonoids: Quercetin, kaempferol derivatives
- Polyacetylenes: Compound with neuroprotective properties
- Neuroprotection: Triterpenoids may protect neurons from amyloid-beta toxicity
- Anti-inflammatory: Modulates neuroinflammatory pathways
- Antioxidant: Reduces oxidative stress in brain tissue
- Memory Enhancement: May improve synaptic plasticity and memory formation
- Diagnosis of Alzheimer's disease
- Mild to moderate cognitive impairment
- Age 50-85 years
- Stable medication regimen
- Significant neurological conditions other than AD
- Psychiatric disorders that could affect participation
- Use of other herbal supplements within 30 days
- Safety and tolerability assessment
- Adverse event monitoring
- Pharmacokinetic profiling
- Cognitive function measures (MMSE, ADAS-Cog)
- Quality of life assessments
- Biomarker analysis
The trial is currently recruiting participants. Results are expected to provide insights into the safety profile and potential cognitive benefits of Centella asiatica in Alzheimer's disease patients.
Based on the triterpenoid mechanisms, the trial aims to demonstrate:
- Neuroprotection: Reduced neuronal death from amyloid-beta toxicity
- Cognitive Stabilization: Maintained or improved cognitive function
- Safety Profile: Acceptable tolerability in AD patients
The expected outcomes are derived from the compound's mechanisms:
- Triterpenoid Neuroprotection: Asiaticoside and madecassoside protect against Aβ-induced cytotoxicity through upregulating antioxidant defenses
- Anti-inflammatory Effects: Modulates neuroinflammation via NF-κB pathway inhibition
- Synaptic Plasticity: May enhance memory through improved hippocampal function
- NCT05591027 - Centella asiatica Alzheimer's Trial
- Centella asiatica: a review of its medicinal properties and therapeutic applications
- Asiaticoside and memory enhancement in Alzheimer's models